Archives

  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • 2021-12
  • 2021-11
  • 2021-10
  • 2021-09
  • 2021-08
  • 2021-07
  • 2021-06
  • 2021-05
  • 2021-04
  • 2021-03
  • 2021-02
  • 2021-01
  • 2020-12
  • 2020-11
  • 2020-10
  • 2020-09
  • 2020-08
  • 2020-07
  • 2020-06
  • 2020-05
  • 2020-04
  • 2020-03
  • 2020-02
  • 2020-01
  • 2019-12
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • 2019-06
  • 2019-05
  • 2019-04
  • 2018-07

    • EZ Cap™ Human PTEN mRNA (ψUTP): Pseudouridine-Modified mR...

    2026-01-26

    EZ Cap™ Human PTEN mRNA (ψUTP): Pseudouridine-Modified mRNA for Robust Tumor Suppressor Expression

    Executive Summary: EZ Cap™ Human PTEN mRNA (ψUTP) (SKU R1026, APExBIO) is a high-purity, in vitro transcribed mRNA encoding full-length human PTEN with a Cap1 structure and pseudouridine triphosphate (ψUTP) modifications, provided at 1 mg/mL in 1 mM sodium citrate buffer (pH 6.4) (APExBIO). PTEN is a critical tumor suppressor that antagonizes PI3K-mediated Akt pathway activation, a major driver of oncogenic signaling and therapeutic resistance (Dong et al., 2022). The Cap1 structure and ψUTP modification increase mRNA stability, translation efficiency, and reduce innate immune recognition in mammalian cells. This reagent is validated for restoring PTEN expression and inhibiting PI3K/Akt signaling in resistant cancer models. Proper handling is essential for activity retention, including storage at -40°C and use of RNase-free reagents (APExBIO).

    Biological Rationale

    PTEN (phosphatase and tensin homolog) is a central tumor suppressor that directly dephosphorylates phosphatidylinositol (3,4,5)-trisphosphate (PIP3), counteracting the activity of phosphoinositide 3-kinase (PI3K) (Dong et al., 2022). Loss of PTEN function is frequently observed in diverse human cancers, leading to constitutive activation of the PI3K/Akt signaling pathway, which promotes cell proliferation, survival, and therapeutic resistance. Restoration of PTEN expression suppresses Akt phosphorylation and can reverse resistance to targeted therapies in multiple cancer models. mRNA-based strategies allow transient, non-integrating restoration of PTEN function, minimizing off-target risks.

    Mechanism of Action of EZ Cap™ Human PTEN mRNA (ψUTP)

    EZ Cap™ Human PTEN mRNA (ψUTP) is synthesized by in vitro transcription, incorporating pseudouridine triphosphate (ψUTP) in place of uridine to suppress innate immune activation and enhance stability (APExBIO). The Cap1 structure, installed enzymatically using Vaccinia virus capping enzyme (VCE), 2'-O-methyltransferase, GTP, and S-adenosylmethionine (SAM), is optimized for recognition by mammalian translation machinery and further reduces immunogenicity compared to Cap0. The full-length PTEN open reading frame (1467 nucleotides) is followed by a synthetic poly(A) tail for stability and translation efficiency. Upon transfection, the mRNA is translated in the cytoplasm, yielding functional PTEN protein. Restored PTEN expression antagonizes PI3K, resulting in reduced Akt phosphorylation and suppression of pro-tumorigenic signaling (Dong et al., 2022).

    Evidence & Benchmarks

    • PTEN mRNA delivered via nanoparticles restores PTEN protein levels and blocks PI3K/Akt signaling in trastuzumab-resistant breast cancer cells (Dong et al., 2022, Fig. 4C-D).
    • Pseudouridine-modified mRNAs (ψUTP) show increased mRNA stability and reduced innate immune activation compared to unmodified transcripts (Dong et al., 2022, Section 3.4).
    • Cap1 structures yield higher translation efficiency and lower immunogenicity in mammalian systems than Cap0 (APExBIO datasheet).
    • EZ Cap™ Human PTEN mRNA (ψUTP) supports robust expression at ≥1 mg/mL in 1 mM sodium citrate buffer, pH 6.4, suitable for in vitro and in vivo applications (APExBIO).
    • Repeated freeze-thaw cycles or RNase contamination can significantly degrade mRNA integrity and reduce functional rescue (Gens Bio, 2023).

    This article extends prior discussion in "EZ Cap™ Human PTEN mRNA (ψUTP): Next-Generation Tools for..." by directly benchmarking evidence for mRNA stability and immune evasion, and clarifies workflow parameters overviews presented in "Enhancing Cancer Assays with EZ Cap™ Human PTEN mRNA (ψUTP)..." with new, actionable data.

    Applications, Limits & Misconceptions

    EZ Cap™ Human PTEN mRNA (ψUTP) is suited for:

    • Cell-based cancer research where restoration of PTEN function is desired.
    • Studies of PI3K/Akt signaling pathway inhibition and reversal of therapeutic resistance.
    • Preclinical evaluation of mRNA-based gene therapy tools.

    It is not a direct therapeutic; all use is for research only. mRNA transfection efficiency depends on cell type, delivery method, and reagent choice. Direct addition to serum-containing medium without transfection reagent results in rapid degradation. Not suitable for applications requiring stable, long-term PTEN expression or genomic integration.

    Common Pitfalls or Misconceptions

    • Misconception: EZ Cap™ Human PTEN mRNA (ψUTP) can be added directly to serum-containing media.
      Fact: Transfection reagents are required for mRNA uptake; direct addition leads to rapid degradation.
    • Misconception: Repeated freeze-thaw cycles do not affect mRNA.
      Fact: Multiple cycles degrade mRNA and reduce activity; aliquoting is recommended (Gens Bio, 2023).
    • Misconception: All Cap structures perform equally in mammalian cells.
      Fact: Cap1 structure yields superior translation and lower immunogenicity versus Cap0 (APExBIO).
    • Limit: Not compatible with direct in vivo injection without specialized delivery (e.g., nanoparticles) (Dong et al., 2022).
    • Limit: Does not result in permanent genomic alteration; effects are transient.

    Workflow Integration & Parameters

    • Supplied at 1 mg/mL in 1 mM sodium citrate buffer, pH 6.4.
    • Store at -40°C or below; ship on dry ice.
    • Handle on ice; avoid vortexing; use RNase-free consumables and reagents.
    • Aliquot to reduce freeze-thaw cycles; discard unused aliquots after thawing.
    • Transfect using lipid-based or electroporation methods validated for mRNA delivery.
    • Do not add directly to serum or serum-containing medium without a suitable transfection reagent.
    • For cell-based assays, monitor PTEN protein by western blot or immunofluorescence at 6–48 hours post-transfection.

    For comprehensive protocol recommendations and troubleshooting, see "Solving Lab Challenges with EZ Cap™ Human PTEN mRNA (ψUTP)...", which this article updates with new evidence on mRNA integrity controls.

    Conclusion & Outlook

    EZ Cap™ Human PTEN mRNA (ψUTP) provides a robust, validated tool for transient PTEN restoration in mammalian systems, enabling direct manipulation of the PI3K/Akt signaling axis in cancer research. Its Cap1 and pseudouridine modifications maximize stability and minimize immune activation, as supported by both product documentation and peer-reviewed evidence (Dong et al., 2022). For further details, product specifications, and ordering, visit the official EZ Cap™ Human PTEN mRNA (ψUTP) product page. APExBIO continues to support translational researchers with advanced mRNA tools for pathway-specific functional studies.